127 related articles for article (PubMed ID: 19842844)
1. Infrequently methylated event at sites -181 to -9 within the 5' CpG island of E-cadherin in non-small cell lung cancer.
Liu RY; Lei Z; Li W; Xu L; Liu Z; Chen XF; Zhao J; Zhang HT
Exp Lung Res; 2009 Sep; 35(7):541-53. PubMed ID: 19842844
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes of downregulation of E-cadherin gene expression in non-small cell lung cancer.
Zheng SY; Hou JY; Zhao J; Jiang D; Ge JF; Chen S
Asian Pac J Cancer Prev; 2012; 13(4):1557-61. PubMed ID: 22799366
[TBL] [Abstract][Full Text] [Related]
3. Multiple gene methylation of nonsmall cell lung cancers evaluated with 3-dimensional microarray.
Wang Y; Zhang D; Zheng W; Luo J; Bai Y; Lu Z
Cancer; 2008 Mar; 112(6):1325-36. PubMed ID: 18286531
[TBL] [Abstract][Full Text] [Related]
4. Promoter-hypermethylation associated defective expression of E-cadherin in primary non-small cell lung cancer.
Wang G; Hu X; Lu C; Su C; Luo S; Luo ZW
Lung Cancer; 2008 Nov; 62(2):162-72. PubMed ID: 18468719
[TBL] [Abstract][Full Text] [Related]
5. Aberrant methylation of H-cadherin (CDH13) promoter is associated with tumor progression in primary nonsmall cell lung carcinoma.
Kim JS; Han J; Shim YM; Park J; Kim DH
Cancer; 2005 Nov; 104(9):1825-33. PubMed ID: 16177988
[TBL] [Abstract][Full Text] [Related]
6. Frequent silencing of the candidate tumor suppressor PCDH20 by epigenetic mechanism in non-small-cell lung cancers.
Imoto I; Izumi H; Yokoi S; Hosoda H; Shibata T; Hosoda F; Ohki M; Hirohashi S; Inazawa J
Cancer Res; 2006 May; 66(9):4617-26. PubMed ID: 16651412
[TBL] [Abstract][Full Text] [Related]
7. Aberrant methylation of E-cadherin and H-cadherin genes in nonsmall cell lung cancer and its relation to clinicopathologic features.
Kim DS; Kim MJ; Lee JY; Kim YZ; Kim EJ; Park JY
Cancer; 2007 Dec; 110(12):2785-92. PubMed ID: 17960794
[TBL] [Abstract][Full Text] [Related]
8. Methylated +322-327 CpG site decreases hOGG1 mRNA expression in non-small cell lung cancer.
Zeng Y; Zhu J; Qin H; Shen D; Lei Z; Li W; Ding Z; Huang JA; Liu Z
Oncol Rep; 2017 Jul; 38(1):529-537. PubMed ID: 28586012
[TBL] [Abstract][Full Text] [Related]
9. Methylated +58CpG site decreases DCN mRNA expression and enhances TGF-β/Smad signaling in NSCLC cells with high metastatic potential.
Qian Q; Shi X; Lei Z; Zhan L; Liu RY; Zhao J; Yang B; Liu Z; Zhang HT
Int J Oncol; 2014 Mar; 44(3):874-82. PubMed ID: 24424784
[TBL] [Abstract][Full Text] [Related]
10. Defective expression of transforming growth factor beta receptor type II is associated with CpG methylated promoter in primary non-small cell lung cancer.
Zhang HT; Chen XF; Wang MH; Wang JC; Qi QY; Zhang RM; Xu WQ; Fei QY; Wang F; Cheng QQ; Chen F; Zhu CS; Tao SH; Luo Z
Clin Cancer Res; 2004 Apr; 10(7):2359-67. PubMed ID: 15073112
[TBL] [Abstract][Full Text] [Related]
11. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
Nakata S; Sugio K; Uramoto H; Oyama T; Hanagiri T; Morita M; Yasumoto K
Cancer; 2006 May; 106(10):2190-9. PubMed ID: 16598757
[TBL] [Abstract][Full Text] [Related]
12. CpG methylation of promoter region inactivates E-cadherin gene in renal cell carcinoma.
Nojima D; Nakajima K; Li LC; Franks J; Ribeiro-Filho L; Ishii N; Dahiya R
Mol Carcinog; 2001 Sep; 32(1):19-27. PubMed ID: 11568972
[TBL] [Abstract][Full Text] [Related]
13. Aberrant methylation of TMS1 in small cell, non small cell lung cancer and breast cancer.
Virmani A; Rathi A; Sugio K; Sathyanarayana UG; Toyooka S; Kischel FC; Tonk V; Padar A; Takahashi T; Roth JA; Euhus DM; Minna JD; Gazdar AF
Int J Cancer; 2003 Aug; 106(2):198-204. PubMed ID: 12800194
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic inactivation of laminin-5-encoding genes in lung cancers.
Sathyanarayana UG; Toyooka S; Padar A; Takahashi T; Brambilla E; Minna JD; Gazdar AF
Clin Cancer Res; 2003 Jul; 9(7):2665-72. PubMed ID: 12855645
[TBL] [Abstract][Full Text] [Related]
15. Mapping the methylation pattern by bisulfite genomic sequencing of the E-cadherin promoter CpG island in nasopharyngeal carcinoma.
Kao RH; Huang LC; Hsu YH
Anticancer Res; 2002; 22(6C):4109-13. PubMed ID: 12553040
[TBL] [Abstract][Full Text] [Related]
16. Promoter methylation-mediated silencing of β-catenin enhances invasiveness of non-small cell lung cancer and predicts adverse prognosis.
Miao Y; Wang L; Zhang X; Xu X; Jiang G; Fan C; Liu Y; Lin X; Yu J; Zhang Y; Wang E
PLoS One; 2014; 9(11):e112258. PubMed ID: 25396757
[TBL] [Abstract][Full Text] [Related]
17. Expression of E-cadherin and nm23 is associated with the clinicopathological factors of human non-small cell lung cancer in China.
Chen XF; Zhang HT; Qi QY; Sun MM; Tao LY
Lung Cancer; 2005 Apr; 48(1):69-76. PubMed ID: 15777972
[TBL] [Abstract][Full Text] [Related]
18. [CpG island methylation of E-cadherin gene promoter in gastric carcinoma].
Zhou YN; Xu CP; Han B; Ji R
Ai Zheng; 2005 Oct; 24(10):1220-4. PubMed ID: 16219136
[TBL] [Abstract][Full Text] [Related]
19. 5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer.
Zöchbauer-Müller S; Fong KM; Maitra A; Lam S; Geradts J; Ashfaq R; Virmani AK; Milchgrub S; Gazdar AF; Minna JD
Cancer Res; 2001 May; 61(9):3581-5. PubMed ID: 11325823
[TBL] [Abstract][Full Text] [Related]
20. Connexin 43, E-cadherin, beta-catenin and ZO-1 expression, and aberrant methylation of the connexin 43 gene in NSCLC.
Jinn Y; Inase N
Anticancer Res; 2010 Jun; 30(6):2271-8. PubMed ID: 20651379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
